APA (7th ed.) Citation

K, Q., QR, C., M, H., ZT, W., Y, L., HG, L., . . . Y, Z. (2023). Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: A multicenter, open-label, single-arm, phase II study (ICAPE). Investigational new drugs, 41(1), 44. https://doi.org/10.1007/s10637-022-01316-5

Chicago Style (17th ed.) Citation

K, Qian, et al. "Icotinib, an EGFR Tyrosine Kinase Inhibitor, as Adjuvant Therapy for Patients with Stage IIA-IIIA EGFR-mutant Non-small-cell Lung Adenocarcinoma: A Multicenter, Open-label, Single-arm, Phase II Study (ICAPE)." Investigational New Drugs 41, no. 1 (2023): 44. https://doi.org/10.1007/s10637-022-01316-5.

MLA (9th ed.) Citation

K, Qian, et al. "Icotinib, an EGFR Tyrosine Kinase Inhibitor, as Adjuvant Therapy for Patients with Stage IIA-IIIA EGFR-mutant Non-small-cell Lung Adenocarcinoma: A Multicenter, Open-label, Single-arm, Phase II Study (ICAPE)." Investigational New Drugs, vol. 41, no. 1, 2023, p. 44, https://doi.org/10.1007/s10637-022-01316-5.